GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (NSE:AKUMS) » Definitions » Asset Turnover

Akums Drugs and Pharmaceuticals (NSE:AKUMS) Asset Turnover : 0.53 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Akums Drugs and Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Akums Drugs and Pharmaceuticals's Revenue for the six months ended in Sep. 2024 was ₹20,522 Mil. Akums Drugs and Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2024 was ₹38,934 Mil. Therefore, Akums Drugs and Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2024 was 0.53.

Asset Turnover is linked to ROE % through Du Pont Formula. Akums Drugs and Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2024 was 14.15%. It is also linked to ROA % through Du Pont Formula. Akums Drugs and Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2024 was 6.44%.


Akums Drugs and Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Akums Drugs and Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akums Drugs and Pharmaceuticals Asset Turnover Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Asset Turnover
1.24 1.39 1.10 1.19

Akums Drugs and Pharmaceuticals Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Asset Turnover Get a 7-Day Free Trial 0.59 0.51 0.63 0.53 0.53

Competitive Comparison of Akums Drugs and Pharmaceuticals's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akums Drugs and Pharmaceuticals's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Akums Drugs and Pharmaceuticals's Asset Turnover falls into.


;
;

Akums Drugs and Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Akums Drugs and Pharmaceuticals's Asset Turnover for the fiscal year that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=40196.82/( (32665.27+35163.65)/ 2 )
=40196.82/33914.46
=1.19

Akums Drugs and Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=20522/( (35163.65+42704.03)/ 2 )
=20522/38933.84
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Akums Drugs and Pharmaceuticals  (NSE:AKUMS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Akums Drugs and Pharmaceuticals's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=2507.54/17714.955
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(2507.54 / 41044)*(41044 / 38933.84)*(38933.84/ 17714.955)
=Net Margin %*Asset Turnover*Equity Multiplier
=6.11 %*1.0542*2.1978
=ROA %*Equity Multiplier
=6.44 %*2.1978
=14.15 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2024) net income data. The Revenue data used here is two times the semi-annual (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Akums Drugs and Pharmaceuticals's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=2507.54/38933.84
=(Net Income / Revenue)*(Revenue / Total Assets)
=(2507.54 / 41044)*(41044 / 38933.84)
=Net Margin %*Asset Turnover
=6.11 %*1.0542
=6.44 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2024) net income data. The Revenue data used here is two times the semi-annual (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Akums Drugs and Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Akums Drugs and Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Akums Drugs and Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).

Akums Drugs and Pharmaceuticals Headlines

No Headlines